Logos Global Management LP trimmed its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) by 77.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 500,000 shares of the biotechnology company’s stock after selling 1,744,960 shares during the period. Logos Global Management LP owned 0.91% of Astria Therapeutics worth $4,550,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. RA Capital Management L.P. bought a new position in shares of Astria Therapeutics during the first quarter worth about $62,115,000. Perceptive Advisors LLC grew its position in shares of Astria Therapeutics by 82.9% during the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after acquiring an additional 1,814,608 shares during the last quarter. Armistice Capital LLC bought a new position in shares of Astria Therapeutics during the fourth quarter worth about $12,119,000. Artal Group S.A. bought a new position in shares of Astria Therapeutics during the first quarter worth about $12,445,000. Finally, Vanguard Group Inc. grew its position in shares of Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after acquiring an additional 480,184 shares during the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.
Astria Therapeutics Trading Down 3.3 %
NASDAQ:ATXS opened at $12.23 on Tuesday. Astria Therapeutics, Inc. has a twelve month low of $4.26 and a twelve month high of $16.90. The firm has a market cap of $671.59 million, a price-to-earnings ratio of -5.27 and a beta of 0.71. The company has a 50-day moving average of $11.33 and a 200-day moving average of $10.89.
Analysts Set New Price Targets
Several equities analysts have recently commented on the stock. Oppenheimer upped their price target on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Finally, TD Cowen started coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Astria Therapeutics currently has an average rating of “Buy” and an average price target of $25.20.
Check Out Our Latest Analysis on ATXS
About Astria Therapeutics
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
See Also
- Five stocks we like better than Astria Therapeutics
- Financial Services Stocks Investing
- 4 Reasons GlobalFoundries Could Be a Big Winner After Recent Lows
- Market Cap Calculator: How to Calculate Market Cap
- The Average 401k Balance by Age Explained
- How to Evaluate a Stock Before BuyingÂ
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
Want to see what other hedge funds are holding ATXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report).
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.